Skip to main content
 
  • Engineering any genome, at any site, in any way

  • Focused on the advancement of new applications for CRISPR-based technologies

  • Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech

News

Caribou Biosciences Announces Grant of a Key CRISPR-Cas9 Genome Editing Patent in Europe

May 10, 2017
Patent covers foundational CRISPR-Cas9 inventions for which Caribou holds an exclusive license from the University of California and the University of Vienna Claims cover CRISPR-Cas9 compositions for use in any non-cellular and cellular...

Caribou Biosciences Announces Grant of a Key CRISPR-Cas9 Patent in the U.S.

May 2, 2017
BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading company in CRISPR-Cas genome engineering, today announced that the United States Patent and Trademark Office (USPTO) has granted Vilnius University a CRISPR-Cas9...

Our Approach

Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing.  Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole. 

Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.

Learn More...